Coursera Spring Sale
40% Off Coursera Plus Annual!
Grab it
Explore the complex relationship between the gut microbiome and immune therapy resistance in ovarian cancer through this 49-minute keynote presentation by Dr. Melanie Rutkowski from the University of Virginia. Discover how commensal microorganisms influence anti-tumor immune function and contribute to the failure of checkpoint blockade therapies in high-grade serous ovarian cancer patients. Learn about the paradoxical role of TLR5 signaling in the ovarian tumor microenvironment and how it triggers loss of anti-tumor immune function. Examine the central role of myeloid cells in controlling anti-tumor immunity and their reprogramming as a strategy to overcome resistance to immune checkpoint blockade. Understand why current therapeutic strategies targeting tumor-associated mechanisms have shown limited clinical success and explore host-intrinsic factors that drive immune therapy failure. Investigate the lab's groundbreaking research identifying host-intrinsic mechanisms mediated by interactions between immune cells and the host microbiota that lead to checkpoint blockade failure. Gain insights into potential new therapeutic strategies designed to counteract the microbiome's negative effects on anti-tumor immune function specifically for ovarian cancer treatment. The presentation addresses the critical need for complementary therapies to enhance anti-tumor T cell responses and improve patient outcomes, given that approximately 80% of ovarian cancer patients experience recurrence and develop chemotherapy resistance despite initial treatment success.
